Anebulo Pharmaceuticals, Inc. (ANEB) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Anebulo Pharmaceuticals, Inc. (ANEB) Reports In-Line Q4 EPS

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

September 29, 2025 4:05 PM EDT

AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or Anebulo), today announced financial results for the three and twelve months ended June 30, 2025, and recent updates.

Fourth Quarter Fiscal Year 2025 and Subsequent Highlights:

On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose (SAD) study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant is under development for treatment of acute cannabis-induced toxicity in children.... More